Angel Biotechnology – Angel signs new contract with ReNeuron

16 May 2012

Angel Biotechnology Holdings plc

("Angel" or "the Company")

Angel signs new contract with ReNeuron to provide GMP (KOSDAQ: 018290.KQ - news) cell manufacturing services for completion of stroke clinical trial

Angel Biotechnology Holdings plc, (AIM:ABH), the biopharmaceutical contract manufacturer, has signed a new contract with ReNeuron Group (Berlin: RQE.BE - news) plc (AIM:RENE) to perform GMP manufacturing services in support of the final part of the PISCES Phase 1 clinical trial of its ReN001 stem cell therapy for stroke; the value of the contract was not disclosed.

Dr Stewart White, Acting CEO, Angel Biotechnology (Berlin: A3G.BE - news) said: "Angel is very proud to be providing ReNeuron with additional manufacturing support to complete this ground breaking Phase 1 clinical trial. This contract is further recognition of the strong partnership between Angel and ReNeuron, and also reaffirms both companies commitment to provide solutions for a real clinical need."

For further information:

Angel Biotechnology Holdings plc

Lorna Peers, Finance Director +44 (0) 131 445 6077

Stewart White, Acting CEO/Commercial Director http://www.angelbio.com

Read the rest here:
Angel Biotechnology - Angel signs new contract with ReNeuron

Related Posts

Comments are closed.